PI3K at the crossroads of tumor angiogenesis signaling pathways

Molecular and Cellular Oncology

Volumn 2, Issue 2, 2015, Pages

  Soler, Adriana ^a   Angulo Urarte, Ana ^a   Graupera, Mariona ^a  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

angiogenesis; PI3K; tumor extrinsic and intrinsic roles; VEGF

Indexed keywords

EID: 84994074706     PISSN: None     EISSN: 23723556     Source Type: Journal    
DOI: 10.4161/23723556.2014.975624     Document Type: Review

References (82)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 1182-6 1971; PMID:4938153; http://dx.doi.org/10.1056/NEJM197108122850711
2. Folkman J. Tumor angiogenesis. Adv Cancer Res 1974; 19:331-58; PMID:4605404; http://dx.doi.org/10.1016/S0065-230X(08)60058-5
3. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011; 146:873-87; PMID:21925313; http://dx.doi.org/10.1016/j.cell.2011.08.039
4. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007; 8:464-78; PMID:17522591
5. Geudens I, Gerhardt H. Coordinating cell behaviour during blood vessel formation. Development 2011; 138:4569-83; PMID:21965610; http://dx.doi.org/10.1242/dev.062323
6. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8:592-603; PMID:18650835; http://dx.doi.org/10.1038/nrc2442
7. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011; 10:417-27; PMID:21629292; http://dx.doi.org/10.1038/nrd3455
8. Moserle L, Jimenez-Valerio G, Casanovas O. Antiangiogenic therapies: going beyond their limits. Cancer Discov 2014; 4:31-41; PMID:24356098; http://dx.doi.org/10.1158/2159-8290.CD-13-0199
9. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-31; PMID:19249680; http://dx.doi.org/10.1016/j.ccr.2009.01.027
10. Ebos JM., Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15, 232-9; PMID:19249681; http://dx.doi.org/10.1016/j.ccr.2009.01.021
11. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62; PMID:15637262; http://dx.doi.org/10.1126/science.1104819
12. Mesange P, Poindessous V, Sabbah M, Escargueil AE, de Gramont A, Larsen AK. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor. Oncotarget 2014; 5:4709-21; PMID:25015210
13. Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014; 15:143-55; PMID:24411639; http://dx.doi.org/10.1016/S1470-2045(13)70586-2
14. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010; 11:329-41; PMID:20379207; http://dx.doi.org/10.1038/nrm2882
15. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014; 13:140-56; PMID:24481312; http://dx.doi.org/10.1038/nrd4204
16. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci 1997; 22:267-72; PMID:9255069; http://dx.doi.org/10.1016/S0968-0004(97)01061-X
17. Hawkins PT, Anderson KE, Davidson K, Stephens LR. Signalling through Class I PI3Ks in mammalian cells. Biochem Soc Trans 2006; 34:647-62; PMID:17052169
18. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296:1655-7; PMID:12040186; http://dx.doi.org/10.1126/science.296.5573.1655
19. Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol 2012; 13:195-203; PMID:22358332; http://dx.doi.org/10.1038/nrm3290
20. Fritsch R, Downward J. SnapShot: class I PI3K isoform signaling. Cell 2013; 154:940-940 e1; PMID:23953121; http://dx.doi.org/10.1016/j.cell.2013.07.045
21. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473:298-307; PMID:21593862; http://dx.doi.org/10.1038/nature10144
22. Carmeliet P., Angiogenesis in health and disease. Nat Med 2003; 9:653-60; PMID:12778163; http://dx.doi.org/10.1038/nm0603-653
23. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359:843-5; PMID:1279431; http://dx.doi.org/10.1038/359843a0
24. Armulik A, Genove G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell 2011; 21:193-215; PMID:21839917; http://dx.doi.org/10.1016/j.devcel.2011.07.001
25. Schmid MC, Avraamides CJ, Dippold HC, Franco I, Foubert P, Ellies LG, Acevedo LM, Manglicmot JR, Song X, Wrasidlo W, et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression. Cancer Cell 2011; 19:715-27; PMID:21665146; http://dx.doi.org/10.1016/j.ccr.2011.04.016
26. Hirsch E, Ciraolo E, Franco I, Ghigo A, Martini M. PI3K in cancer-stroma interactions: bad in seed and ugly in soil. Oncogene. 2014 Jun 12;33(24):3083-90. http://dx.doi.org/10.1038/onc.2013.265
27. Papakonstanti EA, Zwaenepoel O, Bilancio A, Burns E, Nock GE, Houseman B, Shokat K, Ridley AJ, Vanhaesebroeck B. Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages. J Cell Sci 2008; 121:4124-33; PMID:19033389
28. Ali K., Soond DR, Piñeiro R, Hagemann T, Pearce W, Lim EL, Bouabe H, Scudamore CL, Hancox T, Maecker H, et al. Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 2014; 510:407-11; PMID:24919154; http://dx.doi.org/10.1038/nature13444
29. Martin V, et al. Deletion of the p110beta isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo. Blood 2010; 115:2008-13; PMID:20065293; http://dx.doi.org/10.1182/blood-2009-04-217224
30. Graupera M, Potente M. Regulation of angiogenesis by PI3K signaling networks. Exp Cell Res 2013; 319:1348-55; PMID:23500680; http://dx.doi.org/10.1016/j.yexcr.2013.02.021
31. Graupera M, Guillermet-Guibert J, Foukas LC, Phng LK, Cain RJ, Salpekar A, Pearce W, Meek S, Millan J, Cutillas PR, et al. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 2008; 453:662-6; PMID:18449193; http://dx.doi.org/10.1038/nature06892
32. Ackah E, Yu J, Zoellner S, Iwakiri Y, Skurk C, Shibata R, Ouchi N, Easton RM, Galasso G, Birnbaum MJ, et al. Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. J Clin Invest 2005; 115:2119-27; PMID:16075056
33. Lee MY, Luciano AK, Ackah E, Rodriguez-Vita J, Bancroft TA, Eichmann A, Simons M, Kyriakides TR, Morales-Ruiz M, Sessa WC, et al. Endothelial Akt1 mediates angiogenesis by phosphorylating multiple angiogenic substrates. Proc Natl Acad Sci U S A 2014, 111:12865-70; PMID:25136137; http://dx.doi.org10.1073/pnas.1408472111
34. Gambardella L, Hemberger M, Hughes B, Zudaire E, Andrews S, Vermeren S. PI3K signaling through the dual GTPase-activating protein ARAP3 is essential for developmental angiogenesis. Sci Signal 2010; 3:ra76; PMID:20978237; http://dx.doi.org10.1126/scisignal.2001026
35. Hamada K, Sasaki T, Koni PA, Natsui M, Kishimoto H, Sasaki J, Yajima N, Horie Y, Hasegawa G, Naito M, et al. The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev 2005; 19:2054-65; PMID:16107612
36. Yuan TL, Choi HS, Matsui A, Benes C, Lifshits E, Luo J, Frangioni JV, Cantley LC, Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proc Natl Acad Sci U S A 2008; 105:9739-44; PMID:18621722
37. Nicoli S, Knyphausen CP, Zhu LJ, Lakshmanan A, Lawson ND. miR-221 is required for endothelial tip cell behaviors during vascular development. Dev Cell 2012; 22:418-29; PMID:22340502; http://dx.doi.org/10.1016/j.devcel.2012.01.008
38. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY, Srivastava D. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008; 15:272-84; PMID:18694566; http://dx.doi.org/10.1016/j.devcel.2008.07.008
39. Luo J, Field SJ, Lee JY, Engelman JA, Cantley LC. The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. J Cell Biol 2005; 170, 455-64; PMID:16043515; http://dx.doi.org/10.1083/jcb.200503088
40. Ueki K, Fruman DA, Brachmann SM, Tseng YH, Cantley LC, Kahn CR. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol Cell Biol 2002; 22:965-77; PMID:11784871
41. Jain RK, Carmeliet P. SnapShot: tumor angiogenesis. Cell 2012; 149:1408-1408 e1; PMID:22682256; http://dx.doi.org/10.1016/j.cell.2012.05.025
42. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011; 17:1359-70; PMID:22064426; http://dx.doi.org/10.1038/nm.2537
43. Madeddu P, Kraenkel N, Barcelos LS, Siragusa M, Campagnolo P, Oikawa A, Caporali A, Herman A, Azzolino O, Barberis L, et al. Phosphoinositide 3-kinase gamma gene knockout impairs postischemic neovascularization and endothelial progenitor cell functions. Arterioscler Thromb Vasc Biol 2008; 28:68-76; PMID:17962628
44. Nishishita T, Lin P, C. Angiopoietin 1, PDGF-B, and TGF-beta gene regulation in endothelial cell and smooth muscle cell interaction. J Cell Biochem 2004; 91:584-93; PMID:14755687; http://dx.doi.org/10.1002/jcb.10718
45. Pukac L, Huangpu J, Karnovsky MJ., Platelet-derived growth factor-BB, insulin-like growth factor-I, and phorbol ester activate different signaling pathways for stimulation of vascular smooth muscle cell migration. Exp Cell Res 1998; 242:548-60; PMID:9683541; http://dx.doi.org/10.1006/excr.1998.4138
46. Cospedal R, Abedi H, Zachary I. Platelet-derived growth factor-BB PDGF-BB) regulation of migration and focal adhesion kinase phosphorylation in rabbit aortic vascular smooth muscle cells: roles of phosphatidylinositol 3-kinase and mitogen-activated protein kinases. Cardiovasc Res 1999; 41:708-21; PMID:10435043; http://dx.doi.org/10.1016/S0008-6363(98)00232-6
47. Guillermet-Guibert J, Bjorklof K, Salpekar A, Gonella C, Ramadani F, Bilancio A, Meek S, Smith AJ, Okkenhaug K, Vanhaesebroeck B. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci U S A 2008; 105:8292-7; PMID:18544649; http://dx.doi.org/10.1073/pnas.0707761105
48. Soler A, Serra H, Pearce W, Angulo A, Guillermet-Guibert J, Friedman LS, Viñals F, Gerhardt H, Casanovas O, Graupera M, et al. Inhibition of the p110alpha isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis. J Exp Med 2013; 210:1937-45; PMID:24043760
49. Cooke V G, LeBleu VS, Keskin D, Khan Z, O'Connell JT, Teng Y, Duncan MB, Xie L, Maeda G, Vong S, et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 21:66-81 2012; PMID:22264789
50. Xian X, Håkansson J, Ståhlberg A, Lindblom P, Betsholtz C, Gerhardt H, Semb H. Pericytes limit tumor cell metastasis. J Clin Invest 2006; 116:642-51; PMID:16470244
51. Jiang BH, Zheng JZ, Aoki M, Vogt PK. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci U S A 2000; 97:1749-53; PMID:10677529
52. Skinner HD, Zheng JZ, Fang J, Agani F, Jiang BH. Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J Biol Chem 2004; 279:45643-51; PMID:15337760
53. Fang J, Ding M, Yang L, Liu L, Z, Jiang BH. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal 2007; 19, 2487-97; PMID:17826033; http://dx.doi.org/10.1016/j.cellsig.2007.07.025
54. Xia C, Meng Q, Cao Z, Shi X, Jiang BH. Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression. J Cell Physiol 2006; 209:56-66; PMID:16775835; http://dx.doi.org/10.1002/jcp.20707
55. Hu L, Hofmann J, Jaffe RB. Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma. Clin Cancer Res 2005; 11:8208-12; PMID:16299254; http://dx.doi.org/10.1158/1078-0432.CCR-05-0206
56. Mazure NM, Chen EY, Laderoute KR, Giaccia AJ. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 1997; 90:3322-31; PMID:9345014
57. Saharinen P, Eklund L, Pulkki K, Bono P, Alitalo K. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med 2011; 17:347-62; PMID:21481637; http://dx.doi.org/10.1016/j.molmed.2011.01.015
58. Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol 2013; 31:675-704; PMID:23330955; http://dx.doi.org/10.1146/annurev-immunol-032712-095946
59. Murillo MM, Zelenay S, Nye E, Castellano E, Lassailly F, Stamp G, Downward J. RAS interaction with PI3K p110alpha is required for tumor-induced angiogenesis. J Clin Invest 2014; 124:3601-11; PMID:25003191; http://dx.doi.org/10.1172/JCI74134
60. Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 2013; 10:143-53; PMID:23400000; http://dx.doi.org/10.1038/nrclinonc.2013.10
61. Schnell CR, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PM, Dartois C, Stumm M, Cozens R, Littlewood-Evans A, García-Echeverría C, et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res 2008; 68:6598-607; PMID:18701483; http://dx.doi.org/10.1158/0008-5472.CAN-08-1044
62. Maira, SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 2012; 11:317-28; PMID:22188813; http://dx.doi.org/10.1158/1535-7163.MCT-11-0474
63. Qayum N, Muschel RJ, Im JH, Balathasan L, Koch CJ, Patel S, McKenna WG, Bernhard EJ. Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res 2009; 69:6347-54; PMID:19622766; http://dx.doi.org/10.1158/0008-5472.CAN-09-0657
64. Qayum N, Im J, Stratford MR, Bernhard EJ, McKenna WG, Muschel RJ. Modulation of the tumor microvasculature by phosphoinositide-3 kinase inhibition increases doxorubicin delivery in vivo. Clin Cancer Res 2012; 18:161-9; PMID:22065081; http://dx.doi.org/10.1158/1078-0432.CCR-11-1413
65. Fokas E, Yoshimura M, Prevo R, Higgins G, Hackl W, Maira SM, Bernhard EJ, McKenna WG, Muschel RJ. NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity. Radiat Oncol 2012; 7:48; PMID:22452803; http://dx.doi.org/10.1186/1748-717X-7-48
66. Xu S, Li S, Guo Z, Luo J, Ellis MJ, Ma CX. Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models. Mol Cancer Ther 2013; 12:1665-75; PMID:23689832; http://dx.doi.org/10.1158/1535-7163.MCT-13-0159
67. Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmañà J, Rajendran A, Papa A, Spencer K, Lyssiotis CA, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2012; 2:1048-63; PMID:22915751; http://dx.doi.org/10.1158/2159-8290.CD-11-0336
68. Fokas E, Im JH, Hill S, Yameen S, Stratford M, Beech J, Hackl W, Maira SM, Bernhard EJ, McKenna WG, et al. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res 2012; 72:239-48; PMID:22108822
69. Kong D, Okamura M, Yoshimi H, Yamori T. Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor. Eur J Cancer 2009; 45, 857-65; PMID:19144509; http://dx.doi.org/10.1016/j.ejca.2008.12.007
70. Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, et al. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2014; 32:1202-9; PMID:24663045; http://dx.doi.org/10.1200/JCO.2013.54.0518
71. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012; 30:282-90; PMID:22162589; http://dx.doi.org/10.1200/JCO.2011.36.1360
72. Jia S, Roberts TM, Zhao JJ. Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol 2009; 21:199-208; PMID:19200708
73. Ramadani, F, Bolland DJ, Garcon F, Emery JL, Vanhaesebroeck B, Corcoran AE, Okkenhaug K. The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development. Sci Signal 2010; 3(134):ra60; PMID:20699475; http://dx.doi.org/10.1126/scisignal.2001104
74. So L, Yea SS, Oak JS, Lu M, Manmadhan A, Ke QH, Janes MR, Kessler LV, Kucharski JM, Li LS, et al. Selective inhibition of phosphoinositide 3-kinase p110alpha preserves lymphocyte function. J Biol Chem 2013; 288:5718-31; PMID:23275335; http://dx.doi.org/10.1074/jbc.M112.379446
75. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8:128-35; PMID:11821896; http://dx.doi.org/10.1038/nm0202-128
76. Manegold PC, Paringer C, Kulka U, Krimmel K, Eichhorn ME, Wilkowski R, Jauch KW, Guba M, Bruns CJ.l. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res 2008; 14:892-900; PMID:18245553; http://dx.doi.org/10.1158/1078-0432.CCR-07-0955
77. Vinals F, Chambard JC, Pouyssegur J. p70 S6 kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation. J Biol Chem 1999; 274:26776-82; PMID:10480882; http://dx.doi.org/10.1074/jbc.274.38.26776
78. Julien LA, Carriere A, Moreau J, Roux, PP. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol 2010; 30, 908-21; PMID:19995915; http://dx.doi.org/10.1128/MCB.00601-09
79. Falcon BL, Barr S, Gokhale PC, Chou J, Fogarty J, Depeille P, Miglarese M, Epstein DM, McDonald DM. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res 2011; 71:1573-83; PMID:21363918
80. Tibolla G, Piñeiro R, Chiozzotto D, Mavrommati I, Wheeler AP, Norata GD, Catapano AL, Maffucci T, Falasca M. Class II phosphoinositide 3-kinases contribute to endothelial cells morphogenesis. PLoS One 2013; 8, e53808; PMID:23320105; http://dx.doi.org/10.1371/journal.pone.0053808
81. Yoshioka K, Yoshida K, Cui H, Wakayama T, Takuwa N, Okamoto Y, Du W, Qi X, Asanuma K, Sugihara K, et al. Endothelial PI3K-C2alpha, a class II PI3K, has an essential role in angiogenesis and vascular barrier function. Nat Med 18, 1560-9 2012; PMID:22983395; http://dx.doi.org/10.1038/nm.2928
82. Biswas K, Yoshioka K, Asanuma K, Okamoto Y, Takuwa N, Sasaki T, Takuwa Y. Essential role of class II phosphatidylinositol-3-kinase-C2alpha in sphingosine 1-phosphate receptor-1-mediated signaling and migration in endothelial cells. J Biol Chem 2013; 288:2325-39; PMID:23192342